Dashboard
Manage Tickers

ALLOAllogene Therapeutics, Inc.

Nasdaq allogene.com


$ 2.51 $ -0.07 (-2.71 %)    

Thursday, 05-Sep-2024 15:15:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 459.86 $ 0.43 (0.09 %)
DIA $ 407.95 $ -1.96 (-0.48 %)
SPY $ 548.56 $ -1.34 (-0.24 %)
TLT $ 99.56 $ 0.56 (0.57 %)
GLD $ 232.35 $ 1.92 (0.83 %)
$ 2.51
$ 2.63
$ 2.50 x 1,200
$ 2.51 x 1,301
$ 2.49 - $ 2.63
$ 2.01 - $ 5.78
1,085,531
na
524.87M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-08-2019 12-31-2018 10-K
24 11-21-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-allogene-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Allo...
08/15/2024 11:04:54

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $9 pric...

citigroup-maintains-buy-on-allogene-therapeutics-raises-price-target-to-8
Citigroup Maintains Buy on Allogene Therap...
08/09/2024 22:50:01

Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises the price target fro...

truist-securities-reiterates-buy-on-allogene-therapeutics-lowers-price-target-to-14
Truist Securities Reiterates Buy on Alloge...
08/09/2024 13:06:16

Truist Securities analyst Asthika Goonewardene reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the pric...

oppenheimer-assumes-allogene-therapeutics-at-outperform-lowers-price-target-of-11
Oppenheimer Assumes Allogene Therapeutics ...
08/08/2024 14:17:30

Oppenheimer analyst Matthew Biegler assumes Allogene Therapeutics (NASDAQ:ALLO) with a Outperform rating and lowers Price Ta...

a-closer-look-at-6-analyst-recommendations-for-allogene-therapeutics
A Closer Look at 6 Analyst Recommendations...
08/08/2024 14:01:20

canaccord-genuity-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-14
Canaccord Genuity Maintains Buy on Allogen...
08/08/2024 11:32:52

Canaccord Genuity analyst John Newman maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price target f...

allogene-therapeutics-q2-2024-gaap-eps-035-inline
Allogene Therapeutics Q2 2024 GAAP EPS $(0...
08/07/2024 21:38:32

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate.

cell-therapy-mostly-used-for-blood-cancer-shows-efficacy-in-autoimmune-diseases-as-well-but-there-are-challenges
Cell Therapy Mostly Used For Blood Cancer ...
07/19/2024 17:45:01

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...

allogene-therapeutics-announces-patient-screening-underway-for-pivotal-phase-2-alpha3-trial-at-rocky-mountain-cancer-centers-astera-cancer-care-and-norton-cancer-institute-alpha3-to-offer-car-t-as-first-line-treatment-at-community-cancer-centers-aiming-to-complete-enrollment-by-1h-2026-and-potential-bla-submission-in-2027
Allogene Therapeutics Announces Patient Sc...
07/01/2024 12:31:48

Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Insti...

allogene-therapeutics-initiates-phase-2-trial-investigating-cemacabtagene-ansegedleucel-as-part-of-first-line-treatment-for-patients-with-large-b-cell-lymphoma-likely-to-relapse
Allogene Therapeutics Initiates Phase 2 Tr...
06/20/2024 12:38:44

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First P...

analyst-ratings-for-allogene-therapeutics
Analyst Ratings For Allogene Therapeutics
05/31/2024 12:00:17

piper-sandler-initiates-coverage-on-allogene-therapeutics-with-overweight-rating-announces-price-target-of-11
Piper Sandler Initiates Coverage On Alloge...
05/31/2024 09:53:54

Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and anno...

why-james-hardie-industries-shares-are-trading-lower-by-around-14-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why James Hardie Industries Shares Are Tra...
05/21/2024 17:36:28

why-larimar-therapeutics-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
Why Larimar Therapeutics Shares Are Tradin...
05/21/2024 12:12:19

oppenheimer-maintains-outperform-on-allogene-therapeutics-lowers-price-target-to-13
Oppenheimer Maintains Outperform on Alloge...
05/21/2024 12:00:55

Oppenheimer analyst Mark Breidenbach maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and lowers the price ta...

hc-wainwright--co-maintains-buy-on-allogene-therapeutics-lowers-price-target-to-9
HC Wainwright & Co. Maintains Buy on Allog...
05/16/2024 11:49:05

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and lowers the price t...

breaking-down-allogene-therapeutics-5-analysts-share-their-views
Breaking Down Allogene Therapeutics: 5 Ana...
05/15/2024 19:02:31

truist-securities-maintains-buy-on-allogene-therapeutics-maintains-17-price-target
Truist Securities Maintains Buy on Allogen...
05/15/2024 18:17:40

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $17 pr...

why-arcutis-biotherapeutics-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket
Why Arcutis Biotherapeutics Shares Are Tra...
05/15/2024 12:14:56

dlocal-allogene-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
DLocal, Allogene Therapeutics And Other Bi...
05/15/2024 10:12:21

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION